Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
Active, not recruiting · Phase 2 · NCT02899052
Conditions: Multiple Myeloma
At a glance
- Research payments reported, 2025
- $158,873
- U.S. investigators named
- 11
- Sites paid
- 11
- Planned or actual enrollment
- 120
About the trial
- Sponsor
- AbbVie (with Genentech, Inc, Onyx Therapeutics, Inc.)
- Tested
- Carfilzomib (drug), Venetoclax (drug), Dexamethasone (drug)
- Dates
- Started 2017-01-19; completion 2027-06
- Results posted
- Not yet
A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy. Part 4 of this study is currently enrolling.
From ClinicalTrials.gov, last updated 2025-08-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $158,873 in research payments for this study in 2025 (47 payments).
Products named: Venclexta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Luciano Costa Hematology & Oncology · Birmingham, AL
- Frits Van Rhee, MD Hematology & Oncology · Little Rock, AR
- Jonathan L. Kaufman, M.D. Medical Oncology · Atlanta, GA
- Felix A. Mensah, MD Hematology · Indianapolis, IN
- Viran R. Holden, M.D. Medical Oncology · Monett, MO
- Ravi Vij, MD Medical Oncology · Saint Louis, MO
- Cristina Gasparetto, M.D. Infectious Disease · Durham, NC
- Fernado Cabanillas, MD Hematology & Oncology · San Juan, PR
- Larry D. Anderson JR., M.D. , PHD Medical Oncology · Dallas, TX
- Douglas W. Sborov, M.D. Hematology & Oncology · Salt Lake City, UT
- Syed N. Haider, M.D. Hematology & Oncology · Milwaukee, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Alabama Hospital, AL $70,611
- Indiana Blood and Marrow Transplant $18,180
- Duke University $16,113
- Emory University Hospital, GA $15,344
- University of Texas Southwestern Medical Center $13,024
- American Oncology PArtners DBA Oncology Hematology Associates $9,623
- University of Utah Hospital and Clinics, UT $7,961
- Washington University in St Louis $2,431
- Aurora Research Institute LLC $2,336
- Auxilio Mutuo Hospital, PR $2,000
- University of Arkansas Medical Sciences, AR $1,250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.